WO2023175583 - METHODS OF TREATING BONE FRAGILITY SYNDROMES
National phase entry is expected:
Publication Number
WO/2023/175583
Publication Date
21.09.2023
International Application No.
PCT/IB2023/052645
International Filing Date
17.03.2023
Title **
[English]
METHODS OF TREATING BONE FRAGILITY SYNDROMES
[French]
MÉTHODES DE TRAITEMENT DE SYNDROMES DE FRAGILITÉ OSSEUSE
Applicants **
INNOSKEL
Inventors
GOUZE, Elvire
FAVRE, David
Priority Data
63/269,519
17.03.2022
US
63/269,520
17.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3378 | |
| EPO | Filing, Examination, Granting | 23664 | |
| Japan | Filing, Examination, Granting | 2980 | |
| South Korea | Filing, Examination, Granting | 3690 | |
| USA | Filing, Examination, Granting | 9990 |
Total:
43,702
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to methods of modulating delivery of a polynucleotide of interest by altering the route of administration. Additionally, the present invention relates to methods of treating bone fragility syndromes, for example osteogenesis imperfect. More particularly, the present invention relates to targeting gene therapy compositions to bone by providing the composition by intraperitoneal administration.[French]
La présente invention concerne des méthodes de modulation de l'administration d'un polynucléotide d'intérêt par modification de la voie d'administration. De plus, la présente invention concerne des méthodes de traitement de syndromes de fragilité osseuse, par exemple de l'ostéogenèse imparfaite. Plus particulièrement, la présente invention concerne le ciblage de compositions de thérapie génique sur un os en fournissant la composition par administration intrapéritonéale.